AVRO / After Fabry Trial Setback, Avrobio Hopes Rebound With Lysosomal Storage Disorder Data

Here is how AVROBIO, Inc. (AVRO) and DaVita HealthCare (DVA) have performed compared to their sector so far this year. more_horizontal

Here is how AVROBIO, Inc. (AVRO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year. more_horizontal

After monetizing one of its pipeline candidates, Avrobio has cash well in excess of its market cap. The company announced its search for strategic alt more_horizontal

AVROBIO (AVRO) announces its decision to halt all development programs in its quest to explore strategic alternatives. The stock of the company surges more_horizontal

AVROBIO (NASDAQ: AVRO ) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NYSE: NVS ). This deal has more_horizontal

AVROBIO Inc (NASDAQ: AVRO) reported new interim data from the Phase 1/2 gene therapy trial of AVR-RD-04 for cystinosis. Cystinosis is a condition c more_horizontal

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year af more_horizontal

Avrobio Inc's AVRO gene therapy for a rare lysosomal storage disorder showed potential durability in the first three patients more than one year af more_horizontal